Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Eton Pharmaceuticals (ETON) over the last 7 years, with Dec 2024 value amounting to $32.6 million.

  • Eton Pharmaceuticals' Cash from Financing Activities rose 204.23% to $394,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $33.4 million, marking a year-over-year increase of 2694.48%. This contributed to the annual value of $32.6 million for FY2024, which is 3505.75% up from last year.
  • As of FY2024, Eton Pharmaceuticals' Cash from Financing Activities stood at $32.6 million, which was up 3,505.75% from -$957,000 recorded in FY2023.
  • In the past 5 years, Eton Pharmaceuticals' Cash from Financing Activities registered a high of $32.6 million during FY2024, and its lowest value of -$957,000 during FY2023.
  • Over the past 3 years, Eton Pharmaceuticals' median Cash from Financing Activities value was -$134,000 (recorded in 2022), while the average stood at $10.5 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Cash from Financing Activities tumbled by 614.18% in 2023, and later spiked by 3,505.75% in 2024.
  • Over the past 5 years, Eton Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $31.6 million in 2020, then crashed by 98.76% to $391,000 in 2021, then tumbled by 134.27% to -$134,000 in 2022, then plummeted by 614.18% to -$957,000 in 2023, then soared by 3,505.75% to $32.6 million in 2024.